This nationwide cohort study confirms the clinical value of the wearable cardioverter-defibrillator for patients at high risk of sudden cardiac death outside the US healthcare system.
This large cohort represents the first nationwide evaluation of WCD use in patients outside the US healthcare system and confirms the overall value of the WCD in German treatment pathways.
Wäßnig et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: